Clinical Information
Gen. Code and Des.
30773 amphotericin B liposome INTRAVEN VIAL 50 MG
GCN and Des.
7387 amphotericin B liposome INTRAVEN VIAL 50 MG
Strength
50MG
Dose Form
VIAL (EA)
Product Category
RX Pharmaceuticals
Fine Line Class
850085008510 All Rx Products
DEA Class
NC
OMP Family
AHFS Class
8142800 POLYENE ANTIFUNGALS
Active Ingredients
6390 amphotericin B liposome
Inactive Ingredients
13405 soy
2598 sucrose 57501
AMBISOME- amphotericin injection, powder, lyophilized, for solution
Astellas Pharma US, Inc
DESCRIPTION
AmB isome for Injection is sterile, non-pyrogenic lyophilized product for intravenous infusion. Each vial contains 50 mg of amphotericin B, USP, intercalated into liposomal membrane consisting of approximately 213 mg hydrogenated soy phosphatidylcholine; 52 mg cholesterol, NF; 84 mg distearoylphosphatidylglycerol; 0.64 mg alpha tocopherol, USP; together with 900 mg sucrose, NF; and 27 mg disodium succinate hexahydrate as buffer. Following reconstitution with Sterile Water for Injection, USP, the resulting pH of the suspension is between 5-6.
Mechanism of Action
Amphotericin B, the active ingredient of AmB isome, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. It forms transmembrane channels leading to alterations in cell permeability through which monovalent ions (NA+, K+, H+, and Cl-) leak out of the cell resulting in cell death. While amphotericin has higher affinity for the ergosterol component of the fungal cell membrane, it can also bind to the cholesterol component of the mammalian cell leading to cytotoxicity. AmB isome, the liposomal preparation of amphotericin B, has been shown to penetrate the cell wall of both extracellular and intracellular forms of susceptible fungi.
INDICATIONS AND USAGE
AmB isome is indicated for the following:
Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
Treatment of Cryptococcal Meningitis in HIV infected patients (see DESCRIPTION OF CLINICAL STUDIES).
Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin deoxycholate.
Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmB isome, relapse rates were high following initial clearance of parasites
DOSAGE AND ADMINISTRATION
AmB isome should be administered by intravenous infusion, using controlled infusion device, over period of approximately 120 minutes.
An in-line membrane filter may be used for the intravenous infusion of AmB isome; provided THE MEAN PORE DIAMETER OF THE FILTER IS NOT LESS THAN 1.0 MICRON.
NOTE: An existing intravenous line must be flushed with 5% Dextrose Injection prior to infusion of AmBisome. If this is not feasible, AmBisome must be administered through separate lin
